Cardiff Oncology to Present at the H.C. Wainwright Global Investment Conference

Rhea-AI Summary

Cardiff Oncology, Inc. (Nasdaq: CRDF), a biotechnology firm specializing in PLK1 inhibition for cancer therapies, will engage in a fireside chat and one-on-one meetings at the H.C. Wainwright Global Investment Conference in Miami, Florida, from May 23-26, 2022. The fireside chat is scheduled for May 24, 2022, at 5:00 PM ET. The event is a platform for the company to discuss its innovative therapies, particularly its lead asset, onvansertib, aimed at overcoming treatment resistance in various cancers. A replay will be available on their website following the event.

SAN DIEGO, May 17, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a fireside chat and one-on-one meetings in-person at the H.C. Wainwright Global Investment Conference, which is taking place in Miami, Florida from May 23 – 26, 2022.

Details on the fireside chat can be found below.

H.C. Wainwright Global Investment Conference
Date:	May 24, 2022
Time:	5:00 PM ET
Webcast Link:	https://journey.ct.events/view/584e1f6d-5db2-432b-888c-7a27b587ea43

A replay of the fireside chat will be available by visiting the "Events" section of the Cardiff Oncology website after its conclusion. 

About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers. Our lead asset is onvansertib, a PLK1 inhibitor we are evaluating in combination with standard-of-care (SOC) therapeutics in clinical programs targeting indications such as KRAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, and metastatic castrate-resistant prostate cancer. These programs and our broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SOC. For more information, please visit https://www.cardiffoncology.com.

Cardiff Oncology Contact:
Vicki Kelemen
Chief Operating Officer
858-952-7652
vkelemen@cardiffoncology.com 

Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com 

Media Contact:
Amy Jobe, Ph.D.
LifeSci Communications
315-879-8192
ajobe@lifescicomms.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cardiff-oncology-to-present-at-the-hc-wainwright-global-investment-conference-301548838.html

SOURCE Cardiff Oncology, Inc.

FAQ

When is Cardiff Oncology's fireside chat at the H.C. Wainwright Global Investment Conference?

Cardiff Oncology's fireside chat is scheduled for May 24, 2022, at 5:00 PM ET.

Where is the H.C. Wainwright Global Investment Conference taking place?

The H.C. Wainwright Global Investment Conference is being held in Miami, Florida from May 23 to 26, 2022.

What is the focus of Cardiff Oncology's presentation at the conference?

Cardiff Oncology will focus on its PLK1 inhibitor, onvansertib, and its development for treating various cancers.

How can I access the replay of Cardiff Oncology's fireside chat?

The replay of Cardiff Oncology's fireside chat will be available on the company's website in the Events section after the presentation.

What is Cardiff Oncology's main product?

Cardiff Oncology's main product is onvansertib, a PLK1 inhibitor being evaluated for various cancer treatments.